ATF3 and HNF4A: an oxidative phosphorylation and cholesterol homeostasis-associated diagnostic and therapeutic repurposing framework target for metabolic dysfunction-associated steatohepatitis patients - Takeaways - MDSpire

ATF3 and HNF4A: an oxidative phosphorylation and cholesterol homeostasis-associated diagnostic and therapeutic repurposing framework target for metabolic dysfunction-associated steatohepatitis patients

  • By

  • Guiying Zeng

  • Qi Zhao

  • Li Jiang

  • Dongmei Xie

  • Lin Du

  • Mei Yang

  • Mei Luo

  • Qian Wang

  • July 7, 2026

  • 0 min

Share

  • 1

    Metabolic dysfunction-associated steatohepatitis (MASH) affects about 25% of the global population and can lead to severe liver complications.

  • 2

    Oxidative phosphorylation and cholesterol homeostasis are crucial in the onset and progression of MASH.

  • 3

    Activating Transcription Factor 3 (ATF3) and HNF4A are identified as hub variables associated with MASH pathogenesis.

  • 4

    Alverine and mecamylamine are proposed as potential therapeutic agents for treating MASH targeting ATF3 and HNF4A.

  • 5

    The study highlights the integration of oxidative phosphorylation and cholesterol homeostasis for improving MASH diagnosis and treatment.

Original Source(s)

ATF3 and HNF4A: an oxidative phosphorylation and cholesterol homeostasis-associated diagnostic and therapeutic repurposing framework target for metabolic dysfunction-associated steatohepatitis patients

  • by Guiying Zeng, Qi Zhao, Li Jiang, Dongmei Xie, Lin Du, Mei Yang, Mei Luo, Qian Wang

  • July 7, 2026

Related Content

Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

Malignant peripheral nerve sheath tumor of the ileocecal region: a case report

Association between the C-reactive protein–triglyceride–glucose index and coronary heart disease in metabolic dysfunction-associated steatotic liver disease patients: a cross-sectional study